Quackwatch
Accueil » Ressources » Quackwatch » Be Wary of CardioVision Assessment

Be Wary of CardioVision Assessment

Dr Stephen Barrett

 

 

 

https://www.devicewatch.org/reports/cardiovision.shtml

 

 

 

 

Références

  1. Standard price list. Health Management System, Plano, Texas, Jan 1, 2009.
  2. Greenwood JR. Arterial stiffness index. Page 4 in CardioVision featuring the Arterial Stiffness Index (ASI): Selected letters., papers, and pertinent information. Downloaded from IMDP Web site, March 20, 2010.
  3. Sharma GK. Assessment of test repeatability of arterial stiffness index. Blood Pressure Monitor 10:271-274, 2005.
  4. Cardiovascular disease risk tests. Aetna Clinical Policy Bulletin 0381, Aug 7, 2009.
  5. FDA clearance: K961144. Tourito Engineering Co., Inc., March 12, 1997.
  6. Yellin AK. What are 510(k) clearance and premarket approval? Device Watch, Jan 9, 2009.
  7. Chelation therapy. Westside Naturopathic Clinic Web site, accessed March 21, 2010.
  8. Green S. Thérapie par chélation: déclarations non prouvées et théories mal fondées. Quackwatch.
  9. Atwood KA and others. Why the trial to assess chelation therapy (TACT) should be abandoned. Medscape General Medicine 10(5):115, 2008.
  10. Chappell LT and others. Brachial artery stiffness as an outcomes measurement for EDTA-treated patients with vascular disease. Clinical Practice of Alternative Medicine 1:225-228, 2000.
  11. CardioVision featuring the Arterial Stiffness Index (ASI): Selected letters., papers, and pertinent information. Downloaded from IMDP Web site, March 20, 2010.

Dernière mise à jour le 29 août 2019.

Source: Quackwatch Retour à la page d'accueil

© 2019 Dr Stephen Barrett (version anglaise)
© 2019 Les Sceptiques du Québec (version française)